SCHEMBL21570189

SCHEMBL21570189

Cn1cc(C(=O)O)c(OCCN2CCOCC2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
KDM4E B2RXH2 5/20 0.49
ALDH1A1 P00352 4/20 0.49
SIGMAR1 Q99720 2/20 0.47
TP53 P04637 1/20 0.47
TSHR P16473 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
GAA P10253 1/20 0.47
POLB P06746 1/20 0.46
MAPT P10636 1/20 0.46
HTT P42858 1/20 0.46
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
PRKAB2 O43741 1/20 0.44
PRKAG1 P54619 1/20 0.44
PRKAA2 P54646 1/20 0.44
PRKAA1 Q13131 1/20 0.44
PRKAG3 Q9UGI9 1/20 0.44
PRKAG2 Q9UGJ0 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24158999 0.88 SIGMAR1 (0.47) MEN1KMT2AKDM4EALDH1A1SIGMAR1
SCHEMBL21570271 0.85 SMN1; SMN2 (0.49) MEN1KMT2AKDM4EALDH1A1SIGMAR1
SCHEMBL22849597 0.81 SIGMAR1 (0.46) MEN1KMT2AKDM4EALDH1A1SIGMAR1
SCHEMBL21964548 0.80 SIGMAR1 (0.47) MEN1KMT2AKDM4EALDH1A1SIGMAR1
SCHEMBL21960997 0.79 SIGMAR1 (0.45) MEN1KMT2AKDM4EALDH1A1SIGMAR1
SCHEMBL21724076 0.76 ALDH1A1 (0.42) MEN1KMT2AKDM4EALDH1A1TP53
SCHEMBL3448272 0.76 ALDH1A1 (0.51) MEN1KMT2AKDM4EALDH1A1TP53
SCHEMBL21570238 0.76 TSHR (0.38) KMT2AALDH1A1TSHRHTTPRKAB2
SCHEMBL6042440 0.76 POLB (0.68) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL21960999 0.75 SIGMAR1 (0.44) MEN1KMT2AKDM4EALDH1A1SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4029868-B1 MCL-1 INHIBITORS GILEAD SCIENCES INC (US) 2026-05-20 EP disclosed
CN-117304130-A MCL-1 inhibitors 吉利德科学公司 2023-12-29 CN disclosed
US-20230348494-A1 MCL1 INHIBITORS GILEAD SCIENCES, INC. 2023-11-02 US disclosed
US-20230312490-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2023-10-05 US disclosed
US-20230312490-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2023-10-05 US disclosed
US-20230312490-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2023-10-05 US disclosed
CN-112118845-B MCL-1 inhibitors 吉利德科学公司 2023-06-13 CN disclosed
US-11667652-B2 MCL1 inhibitors GILEAD SCIENCES, INC. (US) 2023-06-06 US disclosed
US-11667652-B2 MCL1 inhibitors GILEAD SCIENCES, INC. (US) 2023-06-06 US disclosed
US-11643400-B2 MCL-1 inhibitors GILEAD SCIENCES, INC. (US) 2023-05-09 US disclosed
US-10988451-B2 MCL-1 inhibitors GILEAD SCIENCES, INC. (US) 2021-04-27 US disclosed
US-10988451-B2 MCL-1 inhibitors GILEAD SCIENCES, INC. (US) 2021-04-27 US disclosed
EP-3793565-A1 MCL-1 INHIBITORS Gilead Sciences, Inc. (US) 2021-03-24 EP disclosed
CN-112118845-A MCL-1 inhibitors 吉利德科学公司 2020-12-22 CN disclosed
US-20200331870-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2020-10-22 US disclosed
US-20200331870-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2020-10-22 US disclosed
US-10703733-B2 MCL-1 inhibitors GILEAD SCIENCES, INC. (US) 2020-07-07 US disclosed
US-10703733-B2 MCL-1 inhibitors GILEAD SCIENCES, INC. (US) 2020-07-07 US disclosed
US-20190352271-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2019-11-21 US disclosed
US-20190352271-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2019-11-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190352271-A1 MCL-1 INHIBITORS MCL1, BCL2L1, BCL2 MEN1 1972/4885KMT2A 2456/4885KDM4E 2079/4885
US-20200331870-A1 MCL-1 INHIBITORS MCL1, BCL2L1, BCL2 MEN1 1972/4885KMT2A 2456/4885KDM4E 2079/4885
US-20230312490-A1 MCL-1 INHIBITORS MCL1, BCL2L1, BCL2 MEN1 1972/4885KMT2A 2456/4885KDM4E 2079/4885
US-10703733-B2 MCL-1 inhibitors MCL1, BCL2L1, BCL2 MEN1 1972/4885KMT2A 2456/4885KDM4E 2079/4885
US-11643400-B2 MCL-1 inhibitors MCL1, BCL2L1, BCL2 MEN1 1972/4885KMT2A 2456/4885KDM4E 2079/4885
US-20230348494-A1 MCL1 INHIBITORS MCL1, BCL2L1, BCLAF1 MEN1 1214/4885KMT2A 2686/4885KDM4E 2717/4885
US-10988451-B2 MCL-1 inhibitors MCL1, BCL2L1, BCL2 MEN1 1972/4885KMT2A 2456/4885KDM4E 2079/4885
US-11667652-B2 MCL1 inhibitors MCL1, BCL2L1, BCLAF1 MEN1 1214/4885KMT2A 2686/4885KDM4E 2717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.